myriad_S_stacked.png
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19. Dezember 2024 16:15 ET | Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
myriad_S_stacked.png
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
10. Dezember 2024 18:26 ET | Myriad Genetics, Inc.
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
myriad_S_stacked.png
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10. Dezember 2024 16:05 ET | Myriad Genetics, Inc.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
myriad_S_stacked.png
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
10. Dezember 2024 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
myriad_S_stacked.png
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09. Dezember 2024 16:05 ET | Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
myriad_S_stacked.png
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
09. Dezember 2024 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
NeuroAge Therapeutics: Revolutionary Brain Health Test Predicts Dementia Risk 30 Years in Advance
25. November 2024 21:01 ET | NeuroAge Therapeutics
NeuroAge Therapeutics launches the NeuroAge Test, a cutting-edge tool predicting dementia risk 30 years early to optimize brain health
baylor-logo-wire-1200x628.jpg
Baylor Genetics Wins BioTech Breakthrough Award
19. November 2024 10:00 ET | Baylor Genetics
Baylor Genetics announced its selection as the 2024 winner of the “Overall Genomics Solution of the Year" from BioTech Breakthrough.
Saudi Arabian Genetic Testing Market
Saudi Arabia Genetic Testing Market and 10 Year Forecast Report 2019-2029, Featuring Anwa Medical Labs, NoorDX, Scientific Laboratories Alliance, ELAJ, Genetrack Saudi Arabia, OncoDNA and More
06. November 2024 05:05 ET | Research and Markets
Dublin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Genetic Testing Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
myriad_S_stacked.png
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
04. November 2024 08:39 ET | Myriad Genetics, Inc.
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing